The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Does short-term androgen depletion add to high-dose radiotherapy (80 Gy) in localized intermediate-risk prostate cancer? Intermediary analysis of GETUG 14 randomized trial (EU-20503/NCT00104741).
B. M. Dubray
Research Funding - Ipsen
V. Beckendorf
No relevant relationships to disclose
S. Guerif
No relevant relationships to disclose
E. Le Prise
No relevant relationships to disclose
A. Reynaud-Bougnoux
No relevant relationships to disclose
J. M. Hannoun Levi
No relevant relationships to disclose
T. D. Nguyen
No relevant relationships to disclose
C. Hennequin
No relevant relationships to disclose
J. Cretin
No relevant relationships to disclose
M. Fayolle-Campana
No relevant relationships to disclose
J. Lagrange
No relevant relationships to disclose
J. Bachaud
No relevant relationships to disclose
D. Azria
Honoraria - Novartis; Roche
Research Funding - Novartis
A. Grangirard
No relevant relationships to disclose
P. Pommier
No relevant relationships to disclose
J. Simon
No relevant relationships to disclose
V. Harter
No relevant relationships to disclose
M. Habibian
No relevant relationships to disclose